Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70911 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Molly Plotkin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Inc., Plainsboro, New Jersey, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Overweight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
Aims
Semaglutide, a GLP‐1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy. Materials and Methods A naïve Bucher ITC was conducted using data from two well‐matched randomized controlled trials: OASIS 4 (once‐daily oral semaglutide 25 mg vs. placebo) and STEP 1 (once‐weekly s.c. semaglutide 2.4 mg vs. placebo). Both studies enrolled adults with obesity or overweight with ≥ 1 weight‐related complication and implemented similar lifestyle changes alongside semaglutide/placebo. The ITC compared percentage change in body weight, the proportion of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, ≥ 20% weight loss, changes in cardiometabolic parameters, and quality of life (IWQoL‐Lite‐CT PF). Safety outcomes were descriptively compared.
Results
Oral and s.c. semaglutide delivered comparable efficacy across all outcomes assessed. While small numerical advantages favoured oral or s.c. semaglutide on some endpoints, the differences and associated uncertainty supported therapeutic equivalence. For percentage weight change, s.c. semaglutide showed a small numerical advantage (estimated treatment difference [ETD]: 1.01%‐points (95% confidence intervals [CI]: −1.61, 3.63) under treatment regimen; 0.55%‐points (95% CI: −2.25, 3.35) under efficacy), but well below the FDA's 5% threshold for clinical relevance. Safety profiles were broadly comparable.
Conclusions
This ITC suggests that oral semaglutide 25 mg and s.c. semaglutide 2.4 mg offer comparable efficacy for weight management in adults with obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk Inc., Plainsboro, New Jersey, USA.
- Novo Nordisk A/S, Søborg, Denmark.
- White Box Health Economics Ltd, Brighton & Hove, UK.
- Petauri Evidence, Bicester, UK.
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Förderung
- Novo Nordisk
Zitieren
APA
Plotkin, M., Ivkovic, M., Smith, I., Rathor, N., Chowdhury, R., Hodkinson, A., & Kushner, R. F. (2026). Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70911
Vancouver
Plotkin M, Ivkovic M, Smith I, Rathor N, Chowdhury R, Hodkinson A, et al. Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70911
BibTeX
@article{Plotkin2026,
author = {Plotkin, Molly and Ivkovic, Milana and Smith, Inger and Rathor, Naveen and Chowdhury, Rohan and Hodkinson, Alexander and Kushner, Robert F},
title = {Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70911}
}
EUVIMED